Cardiac Failure Review最新文献

{"title":"Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.","authors":"Zoltán Papp,&nbsp;Piergiuseppe Agostoni,&nbsp;Julian Alvarez,&nbsp;Dominique Bettex,&nbsp;Stefan Bouchez,&nbsp;Dulce Brito,&nbsp;Vladimir Černý,&nbsp;Josep Comin-Colet,&nbsp;Marisa G Crespo-Leiro,&nbsp;Juan F Delgado,&nbsp;Istvan Édes,&nbsp;Alexander A Eremenko,&nbsp;Dimitrios Farmakis,&nbsp;Francesco Fedele,&nbsp;Cândida Fonseca,&nbsp;Sonja Fruhwald,&nbsp;Massimo Girardis,&nbsp;Fabio Guarracino,&nbsp;Veli-Pekka Harjola,&nbsp;Matthias Heringlake,&nbsp;Antoine Herpain,&nbsp;Leo Ma Heunks,&nbsp;Tryggve Husebye,&nbsp;Višnja Ivancan,&nbsp;Kristjan Karason,&nbsp;Sundeep Kaul,&nbsp;Matti Kivikko,&nbsp;Janek Kubica,&nbsp;Josep Masip,&nbsp;Simon Matskeplishvili,&nbsp;Alexandre Mebazaa,&nbsp;Markku S Nieminen,&nbsp;Fabrizio Oliva,&nbsp;Julius-Gyula Papp,&nbsp;John Parissis,&nbsp;Alexander Parkhomenko,&nbsp;Pentti Põder,&nbsp;Gerhard Pölzl,&nbsp;Alexander Reinecke,&nbsp;Sven-Erik Ricksten,&nbsp;Hynek Riha,&nbsp;Alain Rudiger,&nbsp;Toni Sarapohja,&nbsp;Robert Hg Schwinger,&nbsp;Wolfgang Toller,&nbsp;Luigi Tritapepe,&nbsp;Carsten Tschöpe,&nbsp;Gerhard Wikström,&nbsp;Dirk von Lewinski,&nbsp;Bojan Vrtovec,&nbsp;Piero Pollesello","doi":"10.15420/cfr.2020.03","DOIUrl":"https://doi.org/10.15420/cfr.2020.03","url":null,"abstract":"<p><p>Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced heart failure, right ventricular failure and pulmonary hypertension, cardiac surgery, critical care and emergency medicine. Levosimendan is currently in active clinical evaluation in the US. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, UK and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute heart failure arena in recent times and charts a possible development trajectory for the next 20 years.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e19"},"PeriodicalIF":0.0,"publicationDate":"2020-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/be/cfr-06-e19.PMC7374352.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38203091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart.","authors":"Emilia D'Elia,&nbsp;Michele Senni","doi":"10.15420/cfr.2020.11","DOIUrl":"https://doi.org/10.15420/cfr.2020.11","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has become a pandemic affecting every country in the world. In the province of Bergamo, Italy, more than 2,200 cases of COVID-19 have been reported, which include more than 300 deaths. Most hospitalisations have been at the Papa Giovanni XXIII Hospital. This has imposed a significant burden on our hospital in terms of healthcare personnel, dedicated spaces (including intensive care areas) and time spent by clinicians, who are committed to assisting COVID-19 patients. In this short expert opinion, the authors will focus on new insights related to COVID-19 and the cardiovascular system, and try to investigate the grey areas and uncertainties in this field.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e18"},"PeriodicalIF":0.0,"publicationDate":"2020-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/24/cfr-06-e18.PMC7341260.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38164613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019-associated Acute Respiratory Distress Syndrome: An Initial US Experience at a High-volume Centre.","authors":"Yang Yang,&nbsp;Aniket S Rali,&nbsp;Christian Inchaustegui,&nbsp;Javid Alakbarli,&nbsp;Subhasis Chatterjee,&nbsp;James P Herlihy,&nbsp;Joggy George,&nbsp;Alexis Shafii,&nbsp;Ajith Nair,&nbsp;Leo Simpson","doi":"10.15420/cfr.2020.16","DOIUrl":"https://doi.org/10.15420/cfr.2020.16","url":null,"abstract":"In select COVID-19 patients suffering from severe ARDS refractory to conventional therapy, ECMO might be an outcome altering therapy. Respiratory ECMO Survival Prediction (RESP) score appears to be a reliable prognostication tool in selecting COVID-19 patients most likely to benefit from ECMO. Early and frequent evaluation of critically ill COVID-19 patients for ECMO therapy could facilitate timely initiation, and ultimately, favourable outcomes. ECMO is a finite resource, and thus must be used judiciously, especially in the midst of a pandemic where all resources are stretched thin.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e17"},"PeriodicalIF":0.0,"publicationDate":"2020-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/84/cfr-06-e17.PMC7341259.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38164612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemedicine, Artificial Intelligence and Humanisation of Clinical Pathways in Heart Failure Management: Back to the Future and Beyond.","authors":"Domenico D'Amario,&nbsp;Francesco Canonico,&nbsp;Daniele Rodolico,&nbsp;Josip A Borovac,&nbsp;Rocco Vergallo,&nbsp;Rocco Antonio Montone,&nbsp;Mattia Galli,&nbsp;Stefano Migliaro,&nbsp;Attilio Restivo,&nbsp;Massimo Massetti,&nbsp;Filippo Crea","doi":"10.15420/cfr.2019.17","DOIUrl":"https://doi.org/10.15420/cfr.2019.17","url":null,"abstract":"<p><p>New technologies have been recently introduced to improve the monitoring of patients with chronic syndromes such as heart failure. Devices can now be employed to gather large amounts of data and data processing through artificial intelligence techniques may improve heart failure management and reduce costs. The analysis of large datasets using an artificial intelligence technique is leading to a paradigm shift in the era of precision medicine. However, the assessment of clinical safety and the evaluation of the potential benefits is still a matter of debate. In this article, the authors aim to focus on the development of these new tools and to draw the attention to their transition in daily clinical practice.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e16"},"PeriodicalIF":0.0,"publicationDate":"2020-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/d1/cfr-06-e16.PMC7312813.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38114551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Would You Prescribe Mobile Health Apps for Heart Failure Self-care? An Integrated Review of Commercially Available Mobile Technology for Heart Failure Patients.","authors":"Andrea Mortara,&nbsp;Lucia Vaira,&nbsp;Vittorio Palmieri,&nbsp;Massimo Iacoviello,&nbsp;Ilaria Battistoni,&nbsp;Attilio Iacovoni,&nbsp;Francesca Macera,&nbsp;Daniele Pasqualucci,&nbsp;Mario Bochicchio,&nbsp;Renata De Maria","doi":"10.15420/cfr.2019.11","DOIUrl":"https://doi.org/10.15420/cfr.2019.11","url":null,"abstract":"<p><p>Treatment of chronic diseases, such as heart failure, requires complex protocols based on early diagnosis; self-monitoring of symptoms, vital signs and physical activity; regular medication intake; and education of patients and caregivers about relevant aspects of the disease. Smartphones and mobile health applications could be very helpful in improving the efficacy of such protocols, but several barriers make it difficult to fully exploit their technological potential and produce clear clinical evidence of their effectiveness. App suppliers do not help users distinguish between useless/dangerous apps and valid solutions. The latter are few and often characterised by rapid obsolescence, lack of interactivity and lack of authoritative information. Systematic reviews can help physicians and researchers find and assess the 'best candidate solutions' in a repeatable manner and pave the way for well-grounded and fruitful discussion on their clinical effectiveness. To this purpose, the authors assess 10 apps for heart failure self-care using the Intercontinental Marketing Statistics score and other criteria, discuss the clinical effectiveness of existing solutions and identify barriers to their use in practice and drivers for change.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e13"},"PeriodicalIF":0.0,"publicationDate":"2020-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/75/cfr-06-e13.PMC7277786.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38043322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apps and Online Platforms for Patients with Heart Failure.","authors":"Nida Ahmed,&nbsp;Sabahat Ahmed,&nbsp;Julia Grapsa","doi":"10.15420/cfr.2019.15","DOIUrl":"https://doi.org/10.15420/cfr.2019.15","url":null,"abstract":"<p><p>The use of the internet for health advice and information has burgeoned over recent years. This corresponds with an increasing number of people living with heart failure and, in the context of a greater focus on patient engagement, producing accurate online health information is becoming vitally important. To help meet this need, major cardiology societies have designed dedicated, patient-specific areas on their websites. This article aims to provide an overview of the patient information resources from three main professional societies: the European Society of Cardiology, American Heart Association and American College of Cardiology. A summary of the content of these dedicated websites and two smartphone apps is provided, along with a brief look into the future role of these technologies and resources in supporting both patients and their clinicians in the management of heart failure.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e14"},"PeriodicalIF":0.0,"publicationDate":"2020-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/6a/cfr-06-e14.PMC7277783.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38043323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of Myocardial Injury in Coronavirus Disease 2019.","authors":"Aniket S Rali,&nbsp;Sagar Ranka,&nbsp;Zubair Shah,&nbsp;Andrew J Sauer","doi":"10.15420/cfr.2020.10","DOIUrl":"https://doi.org/10.15420/cfr.2020.10","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) predominantly presents with symptoms of fever, fatigue, cough and respiratory failure. However, it appears to have a unique interplay with cardiovascular disease (CVD); patients with pre-existing CVD are at highest risk for mortality from COVID-19, along with the elderly. COVID-19 contributes to cardiovascular complications including arrhythmias, myocardial dysfunction and myocardial inflammation. Although the exact mechanism of myocardial inflammation in patients with COVID-19 is not known, several plausible mechanisms have been proposed based on early observational reports. In this article, the authors summarise the available literature on mechanisms of myocardial injury in COVID-19.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e15"},"PeriodicalIF":0.0,"publicationDate":"2020-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/f7/cfr-06-e15.PMC7277776.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38047294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiopulmonary Ultrasonography for Severe Coronavirus Disease 2019 Patients in Prone Position.","authors":"Aniket S Rali,&nbsp;Sergio Trevino,&nbsp;Edward Yang,&nbsp;James P Herlihy,&nbsp;Jose Diaz-Gomez","doi":"10.15420/cfr.2020.12","DOIUrl":"https://doi.org/10.15420/cfr.2020.12","url":null,"abstract":"Case Presentation A 50-year old female presented to the emergency department with a 6-day history of fever, progressively worsening cough and shortness of breath. The patient did not report any contact with anyone who had been recently unwell or had been travelling. Upon arrival to the emergency room, the patient was noted to be severely hypoxaemic by pulse oximetry (66%) and in impeding respiratory failure, so she was emergently intubated for mechanical ventilatory support. Immediately post-intubation, arterial blood gas was as follows: pH 7.34, pCO 2 31 mmHg, pO 2 60 mmHg, O 2 saturation 90%, calculated HCO 3 16 mmol/l on FiO 2 of 100% and PaO 2 /FIO 2 ratio of 60. Her ventilatory mode was set at controlled minute ventilation, with a respiratory rate of 24, tidal volume of 300 cc (6 cc/ ideal body weight), positive end-expiratory pressure (PEEP) of 20 cmH 2 O and FiO 2 of 100%. The patient’s chest X-ray at the time of admission showed diffuse bilateral pulmonary opacities consistent with multifocal pneumonia or pulmonary oedema (Figure 1). Polymerase chain reaction (PCR) testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was sent and came back positive after 48 hours.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e12"},"PeriodicalIF":0.0,"publicationDate":"2020-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/0f/cfr-06-e12.PMC7265100.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38023337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence, Data Sensors and Interconnectivity: Future Opportunities for Heart Failure.","authors":"Patrik Bachtiger,&nbsp;Carla M Plymen,&nbsp;Punam A Pabari,&nbsp;James P Howard,&nbsp;Zachary I Whinnett,&nbsp;Felicia Opoku,&nbsp;Stephen Janering,&nbsp;Aldo A Faisal,&nbsp;Darrel P Francis,&nbsp;Nicholas S Peters","doi":"10.15420/cfr.2019.14","DOIUrl":"https://doi.org/10.15420/cfr.2019.14","url":null,"abstract":"<p><p>A higher proportion of patients with heart failure have benefitted from a wide and expanding variety of sensor-enabled implantable devices than any other patient group. These patients can now also take advantage of the ever-increasing availability and affordability of consumer electronics. Wearable, on- and near-body sensor technologies, much like implantable devices, generate massive amounts of data. The connectivity of all these devices has created opportunities for pooling data from multiple sensors - so-called interconnectivity - and for artificial intelligence to provide new diagnostic, triage, risk-stratification and disease management insights for the delivery of better, more personalised and cost-effective healthcare. Artificial intelligence is also bringing important and previously inaccessible insights from our conventional cardiac investigations. The aim of this article is to review the convergence of artificial intelligence, sensor technologies and interconnectivity and the way in which this combination is set to change the care of patients with heart failure.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e11"},"PeriodicalIF":0.0,"publicationDate":"2020-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/04/cfr-06-e11.PMC7265101.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38023336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Clinical Trials in a Pandemic: Immediate Implications of Coronavirus Disease 2019.","authors":"Ernest Spitzer,&nbsp;Ben Ren,&nbsp;Jasper J Brugts,&nbsp;Joost Daemen,&nbsp;Eugene McFadden,&nbsp;Jan Gp Tijssen,&nbsp;Nicolas M Van Mieghem","doi":"10.15420/cfr.2020.07","DOIUrl":"https://doi.org/10.15420/cfr.2020.07","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic started in Wuhan, Hubei Province, China, in December 2019, and by 24 April 2020, it had affected >2.73 million people in 185 countries and caused >192,000 deaths. Despite diverse societal measures to reduce transmission of the severe acute respiratory syndrome coronavirus 2, such as implementing social distancing, quarantine, curfews and total lockdowns, its control remains challenging. Healthcare practitioners are at the frontline of defence against the virus, with increasing institutional and governmental supports. Nevertheless, new or ongoing clinical trials, not related to the disease itself, remain important for the development of new therapies, and require interactions among patients, clinicians and research personnel, which is challenging, given isolation measures. In this article, the authors summarise the acute effects and consequences of the COVID-19 pandemic on current cardiovascular trials.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e09"},"PeriodicalIF":0.0,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/0c/cfr-06-e09.PMC7215493.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37939671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}